Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LRAT | O95237 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GJA1 | P17302 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20713636 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL22639646 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL16688093 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL16577196 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL16577216 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL16589049 | 1.00 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL23743113 | 0.91 | L3MBTL1 (0.44) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL22429030 | 0.87 | L3MBTL1 (0.42) | L3MBTL1MAPTLMNAKDM4EALOX15 | |
| SCHEMBL15459182 | 0.86 | LRAT (0.50) | LMNAKDM4EALOX15TSHRHSD17B10 | |
| SCHEMBL15459179 | 0.86 | L3MBTL1 (0.51) | L3MBTL1MAPTLMNAKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067672-A1 | FLAVONE DERIVATIVE FOR TREATING TUMORS AND USE THEREOF | SICHUAN FUSHENGYUAN TECHNOLOGY CO., LTD (CN) | 2024-02-29 | — | — | US | disclosed |
| US-11572382-B2 | Camptothecin derivatives and preparation methods and applications thereof | TARGET BIOPHARMACEUTICAL TECHNOLOGY SHENZHEN COMPANY LIMITED (CN) | 2023-02-07 | — | — | US | disclosed |
| US-20210246157-A1 | CAMPTOTHECIN DERIVATIVES AND PREPARATION METHODS AND APPLICATIONS THEREOF | Sichuan Fushengyuan Technology Co., Ltd. (CN) | 2021-08-12 | — | — | US | disclosed |
| US-20200297693-A1 | GLUCOSE CONJUGATES OF TRIPTOLIDE, ANALOGS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2020-09-24 | — | — | US | disclosed |
| US-10695319-B2 | Glucose conjugates of triptolide, analogs and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190038596-A1 | GLUCOSE CONJUGATES OF TRIPTOLIDE, ANALOGS AND USES THEREOF | SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190038596-A1 | GLUCOSE CONJUGATES OF TRIPTOLIDE, ANALOGS AND USES THEREOF | SLC2A8, SLC2A4, SLC2A1 | L3MBTL1 843/4885MAPT 3103/4885LMNA 3551/4885 |
| US-11572382-B2 | Camptothecin derivatives and preparation methods and applications thereof | TOP1, TOP2A, TOP2B | L3MBTL1 2382/4885MAPT 4634/4885LMNA 585/4885 |
| US-20200297693-A1 | GLUCOSE CONJUGATES OF TRIPTOLIDE, ANALOGS AND USES THEREOF | SLC2A8, SLC2A4, SLC2A1 | L3MBTL1 843/4885MAPT 3103/4885LMNA 3551/4885 |
| US-20210246157-A1 | CAMPTOTHECIN DERIVATIVES AND PREPARATION METHODS AND APPLICATIONS THEREOF | TOP1, TOP2A, TOP2B | L3MBTL1 2336/4885MAPT 4634/4885LMNA 584/4885 |
| US-20240067672-A1 | FLAVONE DERIVATIVE FOR TREATING TUMORS AND USE THEREOF | TPD52L2, F12, H1-0 | L3MBTL1 216/4885MAPT 4763/4885LMNA 2178/4885 |
| US-10695319-B2 | Glucose conjugates of triptolide, analogs and uses thereof | SLC2A8, SLC2A4, SLC2A1 | L3MBTL1 843/4885MAPT 3103/4885LMNA 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.